Imagion Biosystems Limited (ASX: IBX) has lodged “Notice Pursuant to Section 708A(5)(e) of the Corporations Act” with the Australian Securities Exchange.View Notice Pursuant to Section 708A(5)(e) of the Corporations Act.
Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer
February 19, 2025
MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce